Plus, baby formula is the next overhaul target for Robert F. Kennedy Jr. https://t.co/5rPA5gWb6g ...

⚠️WARNING: FDA Recalls nearly 2000 Products contaminated with bird and rodent feces- The nearly 2,000 products distributed by Minneapolis-based Gold Star Distribution, Inc include Tylenol, Advil, Pringles, Nutella, Cheerios, along with baby formula, pet food, and cosmetics. https://t.co/ARyhfNWFxD ...

Two deaths and scores of hospitalizations show how baby formula makers globally are struggling to balance innovation with safety. Read more: https://t.co/GxeoualwmA📷️: Photo Illustration: 731. Source: Getty Images and Shutterstock https://t.co/ioAp83cqTf ...

Two deaths and scores of hospitalizations show how baby formula makers globally are struggling to balance innovation with safety https://t.co/vd3vEunOxt ...

RT Agnieszka de Sousa 🍒 (@AggieDeSousa)A toxin scare involving baby formula is causing disruption at some of the world's largest food companies.What is cereulide and why it's so stubborn, read in the latest Business of Food newsletter, from @fabiennekatrinhttps://t.co/LJabyZ4Y6Q ...

Core Viewpoint - Danone is recalling specific batches of baby formula in targeted markets due to a toxin contamination scare that originated from Nestle products [1] Company Summary - Danone, a French food and beverage maker, is taking precautionary measures by recalling certain baby formula batches [1] - The recall is part of a broader issue related to toxin contamination that has affected multiple companies in the industry, starting with Nestle [1] Industry Summary - The contamination scare has raised concerns across the food and beverage sector, particularly in baby formula products [1] - Companies in the industry are likely to face increased scrutiny and regulatory challenges as a result of this incident [1]

Core Insights - Abbott Laboratories has projected that its first-quarter profit will fall short of Wall Street expectations due to the need to offer discounts on nutrition products to attract price-sensitive customers, resulting in a significant drop in share prices [1][4] Financial Performance - The company anticipates adjusted earnings per share for the first quarter to be between $1.12 and $1.18, compared to the Wall Street average estimate of $1.19 [2] - In the fourth quarter, Abbott reported sales of $11.5 billion, which was below the average analyst estimate of $11.8 billion. Nutrition sales were particularly disappointing at $1.9 billion, falling short of the $2.19 billion estimate [3] Business Strategy - Abbott is shifting its nutrition business focus towards sustainable volume growth, which may impact performance in the first half of the year but is expected to position the business for long-term success. The company plans to launch eight new nutrition products in 2026 [5] Market Dynamics - The adult nutrition unit, which includes protein-focused drinks for individuals on weight-loss medications, has seen growth in recent quarters. However, the company faces challenges due to lawsuits alleging that its baby formula may cause necrotizing enterocolitis (NEC) in premature infants [6] Segment Performance - Abbott's largest business unit, medical devices, generated $5.67 billion in sales during the fourth quarter, aligning with estimates. This division includes products that assist diabetics in monitoring blood sugar levels [7] - The diagnostics unit has experienced a decline in demand following the pandemic, particularly for Covid-19 tests. Abbott has agreed to acquire Exact Sciences Corp. for approximately $21 billion, which is expected to enhance its diagnostics business by providing access to cancer screening tests [8]

Nestle has recalled a batch of baby formula after routine quality checks detected some issues, Ethiopia's Food and Drug Authority said in a statement on Thursday. ...

Target, Walmart, and Whole Foods will be added as defendants in lawsuits against baby formula maker ByHeart for selling a product potentially contaminated with spores that cause infant botulism. https://t.co/AwIdx8cRBo ...

Core Viewpoint - The U.S. Food and Drug Administration (FDA) has issued warning letters to four major retailers for selling baby formula associated with a bacterial illness outbreak in infants, despite prior advisories [1] Group 1: Regulatory Actions - The FDA's warning letters highlight ongoing concerns regarding the safety of baby formula products in the market [1] - The retailers involved have been identified as continuing to sell products linked to the outbreak, raising questions about compliance with health regulations [1] Group 2: Health Implications - The bacterial illness outbreak has significant implications for infant health, necessitating immediate action from both retailers and regulatory bodies [1] - The situation underscores the importance of stringent safety measures in the baby formula industry to protect vulnerable populations [1]